Amgen (AMGN) EPS & PE Ratio History
Current and historical earning per share (EPS) and price to earnings (PE) ratio for Amgen (AMGN) over the last 10 years. The current PE ratio for Amgen as of September 21, 2017 is 15.26.
|Medical||Medical - Biomedical and Genetics||$137.303B||$22.991B|
|Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.|